The Burden of Adverse Drug Reactions in Africa in the Context of Pharmacogenetics‐Based Clinical Guidelines

Documenti analoghi

• Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy
  di: Michael T. Eadon, et al.
  Pubblicazione: (2025)
• The Persistent Ambiguity of Adverse Drug Reactions
  di: Edward M. Sellers, et al.
  Pubblicazione: (2025)
• Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy
  di: Katherine M. Robinson, et al.
  Pubblicazione: (2024)
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update
  di: Maud Maillard, et al.
  Pubblicazione: (2026)
• Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta‐Blocker Therapy
  di: Julio D. Duarte, et al.
  Pubblicazione: (2024)